Maximizing radiotracer delivery to experimental atherosclerotic lesions with high-dose, negative charge-modified Z2D3 antibody for immunoscintigraphic targeting.

Source:http://linkedlifedata.com/resource/pubmed/id/9199260

Download in:

View as

General Info

PMID
9199260